NeoLight LLC, an ASU spinout and an Arizona based newborn medical device company, today announced it has acquired Phoenix Technology Group LLC (PTG), a leading provider of advanced ophthalmic imaging devices, including a telemedicine platform for retinopathy of prematurity (ROP) screening, a leading cause of blindness in premature infants. The acquisition will expand the NeoLight product portfolio to include the ocular imaging devices Phoenix ICON, Phoenix ICON GO, and the telemedicine platform Phoenix CONNECT (previously known as FocusROP). These products provide advanced ocular imaging through lens and light innovation, providing stunning ocular images that give clinicians the needed speed, confidence, and connectivity for patient exams.


READ ALSO: Here’s how Scottsdale’s Cure Corridor has become a game-changer


With the addition of the Phoenix ICON and Phoenix CONNECT products, NeoLight is expanding its empathy-driven clinical offerings to diagnose and treat newborn conditions. The Phoenix ICON camera system is sold direct in the US and Canada and will now be available through the NeoLight US sales team. In addition, Phoenix ICON is sold through distribution in more than 95 countries around the world. NeoLight plans to build on this distribution network to make the Skylife Neonatal Phototherapy products available around the world giving clinicians access to this best-in-class neonatal phototherapy system.

“Since our founding at Arizona State University, NeoLight’s entire focus has been to deliver the best technologies possible for the newborn care market. The technologies that will be the new gold standard for the coming decades.” said Vivek Kopparthi, Cofounder & Executive Chairman of NeoLight. “PTG’s technologies are state of the art and deeply empathy-driven like ours’. We are excited as this complimentary acquisition also enables us to reach a larger market with greater speed.”

J. Scott Carr, Phoenix Technology Group president and Chief Executive Officer, said, “I am proud of the work the PTG team has accomplished to commercialize breakthrough imaging and telemedicine technology and bring it to clinicians around the world in their fight to save sight. NeoLight and PTG have a shared vision of providing empathy-driven care to newborns. Bringing the Skylife, Phoenix ICON, and Phoenix CONNECT products together opens the door to accelerate the growth and adoption of the full suite of clinical products.”

With this business combination, NeoLight will be well positioned to address significant newborn market needs, including:

• Enhancing newborn eye screening and hyperbilirubinemia detection/treatment product offerings through combined development capabilities with customer focused innovation.

• Distribution of enhanced newborn solutions to more people around the world through an established global sales force.

• Distinguished leadership and experienced employees with commitment to serving the newborn medical community.

The Phoenix MICRON and associated systems will not be part of the NeoLight acquisition and will spin off as a separate entity.